bioAffinity Technologies News Update [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news. Lung Innovations Network Adds CyPath® Lung Test to its Comprehensive Lung Care Practice Lung Innovations Network is incorporating CyPath® Lung, our noninvasive test for the early detection of lung cancer, into its patient-centered practice that offers comprehensive lung care to more than 10,000 patients in central and western Pennsylvania. Lung Innovations Network's multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice. "I see hundreds of patients a year in my clinical practice who can directly benefit from CyPath® Lung, bioAffinity's patient-friendly, noninvasive test for lung cancer," Medical Director Sandeep Bansal, M.D., said. bioAffinity Expands Sales Team for CyPath® Lung National Sales Director Dallas Coleman announced that Cole Koeppen has joined b
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024GlobeNewswire
- Pulmonx Co. (NASDAQ: LUNG) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $17.00 price target on the stock.MarketBeat
- Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Pulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerGlobeNewswire
- Pulmonx: Revisiting Thesis Following Management Change [Seeking Alpha]Seeking Alpha
LUNG
Earnings
- 2/21/24 - Beat
LUNG
Sec Filings
- 4/24/24 - Form 4
- 4/22/24 - Form 144
- 4/9/24 - Form 3
- LUNG's page on the SEC website